全文获取类型
收费全文 | 715篇 |
免费 | 48篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 16篇 |
妇产科学 | 7篇 |
基础医学 | 70篇 |
口腔科学 | 10篇 |
临床医学 | 81篇 |
内科学 | 200篇 |
皮肤病学 | 18篇 |
神经病学 | 34篇 |
特种医学 | 27篇 |
外科学 | 145篇 |
综合类 | 10篇 |
预防医学 | 57篇 |
眼科学 | 27篇 |
药学 | 33篇 |
中国医学 | 6篇 |
肿瘤学 | 21篇 |
出版年
2024年 | 1篇 |
2023年 | 6篇 |
2022年 | 27篇 |
2021年 | 45篇 |
2020年 | 24篇 |
2019年 | 34篇 |
2018年 | 34篇 |
2017年 | 22篇 |
2016年 | 25篇 |
2015年 | 29篇 |
2014年 | 41篇 |
2013年 | 49篇 |
2012年 | 75篇 |
2011年 | 71篇 |
2010年 | 34篇 |
2009年 | 25篇 |
2008年 | 29篇 |
2007年 | 47篇 |
2006年 | 27篇 |
2005年 | 40篇 |
2004年 | 13篇 |
2003年 | 24篇 |
2002年 | 10篇 |
2001年 | 5篇 |
2000年 | 1篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1992年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有765条查询结果,搜索用时 15 毫秒
1.
2.
Mohammad T. Yousafzai Maryam Alavi Heather Valerio Behzad Hajarizadeh Jason Grebely Gregory J. Dore 《Viruses》2022,14(7)
This study aimed to identify the factors associated with timely (within four weeks) HCV RNA testing and timely (within six months) DAA initiation following HCV notification in the DAA era. We conducted a cohort study of people with an HCV notification in NSW, Australia. Notifications of positive HCV serology were linked to administrative datasets. Weights were applied to account for spontaneous clearance. Logistic regression analyses were performed. Among 5582 people with an HCV notification during 2016–2017, 3867 (69%) were tested for HCV RNA, including 2770 (50%) who received timely testing. Among an estimated 3925 people with chronic HCV infection, 2372 (60%) initiated DAA therapy, including 1370 (35%) who received timely treatment. Factors associated with timely HCV RNA testing included age (≥30 years), female sex, non-Aboriginal ethnicity, country of birth being Australia, and no history of drug dependence. Factors associated with timely treatment were age (≥30 years), male sex, non-Aboriginal ethnicity, country of birth being Australia, no history of drug dependence, and HCV/HIV co-infection. In the DAA era, 50% of people with an HCV notification did not receive timely HCV RNA testing. Most people with an HCV infection received therapy; however, DAA initiation was delayed among many. 相似文献
3.
Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
Seyed Hossein Kiaie Mohammad Javad Sanaei Masoud Heshmati Zahra Asadzadeh Iman Azimi Saleh Hadidi Reza Jafari Behzad Baradaran 《药学学报(英文版)》2021,11(5):1083-1097
Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.KEY WORDS: Immune checkpoint, Pancreatic cancer, Tumor microenvironment, Immunotherapy, Clinical development 相似文献
4.
Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. 总被引:4,自引:0,他引:4
Luciano C Amado Karl H Schuleri Anastasios P Saliaris Andrew J Boyle Robert Helm Behzad Oskouei Marco Centola Virginia Eneboe Randell Young Joao A C Lima Albert C Lardo Alan W Heldman Joshua M Hare 《Journal of the American College of Cardiology》2006,48(10):2116-2124
OBJECTIVES: The purpose of this study was to test the hypothesis, with noninvasive multimodality imaging, that allogeneic mesenchymal stem cells (MSCs) produce and/or stimulate active cardiac regeneration in vivo after myocardial infarction (MI). BACKGROUND: Although intramyocardial injection of allogeneic MSCs improves global cardiac function after MI, the mechanism(s) underlying this phenomenon are incompletely understood. METHODS: We employed magnetic resonance imaging (MRI) and multi-detector computed tomography (MDCT) imaging in MSC-treated pigs (n = 10) and control subjects (n = 12) serially for a 2-month period after anterior MI. A sub-endocardial rim of tissue, demonstrated with MDCT, was assessed for regional contraction with MRI tagging. Rim thickness was also measured on gross pathological specimens, to confirm the findings of the MDCT imaging, and the size of cardiomyocytes was measured in the sub-endocardial rim and the non-infarct zone. RESULTS: Multi-detector computed tomography demonstrated increasing thickness of sub-endocardial viable myocardium in the infarct zone in MSC-treated animals (1.0 +/- 0.2 mm to 2.0 +/- 0.3 mm, 1 and 8 weeks after MI, respectively, p = 0.028, n = 4) and a corresponding reduction in infarct scar (5.1 +/- 0.5 mm to 3.6 +/- 0.2 mm, p = 0.044). No changes occurred in control subjects (n = 4). Tagging MRI demonstrated time-dependent recovery of active contractility paralleling new tissue appearance. This rim was composed of morphologically normal cardiomyocytes, which were smaller in MSC-treated versus control subjects (11.6 +/- 0.2 mum vs. 12.6 +/- 0.2 mum, p < 0.05). CONCLUSIONS: With serially obtained MRI and MDCT, we demonstrate in vivo reappearance of myocardial tissue in the MI zone accompanied by time-dependent restoration of contractile function. These data are consistent with a regenerative process, highlight the value of noninvasive multimodality imaging to assess the structural and functional basis for myocardial regenerative strategies, and have potential clinical applications. 相似文献
5.
Amiri Parichehr Naghizadeh Mahsa Baradaran Behzad Saghafi-Asl Maryam Shanehbandi Dariush Mirmajidi Susan 《International journal of diabetes in developing countries.》2019,39(1):66-73
International Journal of Diabetes in Developing Countries - The present study aimed to investigate the association of insulin resistance (IR) with inflammatory gene expression levels, metabolic... 相似文献
6.
High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates 下载免费PDF全文
Reza Khashei Mahintaj Dara Abdollah Bazargani Kamran Bagheri Lankarani Alireza Taghavi Maryam Moeini Behzad Dehghani Maryam Sohrabi 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2016,124(9):787-793
This study aimed to investigate the clarithromycin resistance and its associated molecular mechanisms among Helicobacter pylori isolates from dyspeptic patients in Shiraz, Iran. From January to May 2014, 100 H. pylori strains were isolated from patients with gastroduodenal disorders. The resistance to clarithromycin was quantitatively evaluated, using Epsilometer (E‐test) method. Polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) was performed on all the isolates to detect A2143G and A2142G mutations in 23S rRNA gene. The H. pylori isolation rate was found to be 31.4%. E‐test showed that 20% of isolates were resistant to clarithromycin (MIC ≥ 1 mg/L). MIC of clarithromycin ranged between 0.016 and 24 mg/L. Findings of PCR‐RFLP showed that the A2142G was the most (90%) frequently point mutation, followed by the A2143G (10%). No statistically significant difference was found between H. pylori clarithromycin resistance point mutations and patients’ gender or age. To the best of our knowledge, this is the first report of high frequency of A2142G point mutation in Iran and probably in other regions of the world. Considering the increasing trend of H. pylori resistance to clarithromycin due to these mutations, it is crucial to investigate the new therapeutic approaches against H. pylori infection. 相似文献
7.
Peroxisome proliferator activated receptors (PPARs) are members of the nuclear receptor super family that modulate gene expression upon ligand activation. They are 3 major subtypes of PPARs: alpha, delta (also called beta), and gamma. PPAR-gamma is widely expressed in the cardiovascular system and is involved in the regulation of tissue inflammation and smooth muscle cell growth pathways as well as in lipoprotein metabolism and coagulation cascades. PPAR-gamma ligands of (e.g., rosigitazone and pioglitazone) have been shown to exert antiatherogenic effects both in vitro and in vivo. PPAR-alpha ligands (e.g., clofibrate and benzofibrate) modulate lipoprotein metabolism, and affect inflammation and coagulation cascade. These effects may be helpful in resolving the dilemma arising from studies that showed significant mortality and morbidity benefits of fibrates in the face of minimal changes in HDL-cholesterol levels. The role of PPAR-delta in atherogenesis remains largely unknown, although it appears that PPAR-delta activation affects lipoprotein metabolism. PPAR ligands appear to be promising agents in limiting atherosclerosis; however, large-scale clinical trials are required to assess their safety and efficacy before they can be added to the clinicians' arsenal of antiatherosclerotic agents. 相似文献
8.
Hossein Khorramdelazad Gholamhossein Hassanshahi Behzad Nasiri Ahmadabadi Mohammad Kazemi Arababadi 《Hepatitis monthly》2012,12(11)
Background
The transforming growth factor-β (TGF-β) is an important cytokine with anti-inflammatory properties.Objectives
The main purpose of this study was to compare the serum levels of TGF-β in a group of chronic HBV infected (CHB) patients as well as healthy individuals from South-East of Iran.Patients and Methods
Sixty patients with CHB as well as sixty healthy individuals were enrolled in the study. ELISA technique was applied to measure the serum levels of TGF-β in both groups.Results
Our results revealed that the serum levels of TGF-β were significantly increased in CHB patients in compare to healthy controls.Conclusions
According to this result, it may be concluded that high serum levels of TGF-β may be a mechanism by which immune response against HBV is suppressed. 相似文献9.
10.
Fatemeh Beiraghdar Yunes Panahi Behzad Einollahi Eghlim Nemati Amirhossein Sahebkar Arash Hassanzadeh Hamid T. Khosroshahi Sima A. Azar Javid Safa Sadroddin R. Hashemi Jalal Etemadi Eisa T. Marzony Hamid Noshad 《Saudi Pharmaceutical Journal》2015,23(5):544-548
Background: The efficacy of human recombinant erythropoietins (rHuEPOs) in the treatment of anemia with different etiologies is proven. Development of biosimilar rHuEPO products with lower cost and wider availability is important for the care of anemic patients. Objective: The aim of the present study was to determine the bioequivalence and safety of a biosimilar rHuEPO (Pastopoitin®) and compare it with the innovator product Eprex®, as a standard rHuEPO. Methods: One hundred and seven anemic patients on stable hemodialysis were recruited to this randomized double-blind comparative trial and assigned to either subcutaneous Pastopoitin (n = 50) or Eprex (n = 57). Each study group received rHuEPO at a dose of 80–120 IU/kg/week in 2–3 divided doses for a period of 3 months. Hematologic parameters including Hemoglobin, hematocrit, RBC, EBC, platelet, MCV, MCH and MCHC were checked every 2 weeks. Blood iron, ferritin, TIBC, creatinine, BUN and electrolytes (Na, K, Ca and P) were evaluated monthly over the 3 months. Results: A significant increase in hemoglobin, hematocrit and RBC was observed by the end of study in both Pastopoitin and Eprex groups (p < 0.001). However, these factors were not significantly different between the groups, neither at baseline nor at the end of study (p > 0.05). Likewise, the groups were comparable regarding MCV, MCH, MCHC, iron, ferritin, TIBC, creatinine, BUN and electrolytes at baseline as well as at the end of trial. Adverse events were not serious and occurred with the same frequency in the study groups. Conclusion: Pastopoitin showed comparable efficacy and safety profile with Eprex in anemic patients on hemodialysis. Hence, Pastopoitin may be considered as a rHuEPO with a lower cost and wider availability compared with the innovator product Eprex. 相似文献